Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 330

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 330
---
.

Consolidated
Statements of Operations and Comprehensive Loss

    2024  
    2023 

    For the year ended December 31, 

    2024  
    2023 
  
    Operating expenses: 

    Research and development 
    $7,251,097  
    $7,621,707 
  
    General and administrative 
     8,114,654  
     8,756,767 

    Total operating expenses 
     15,365,751  
     16,378,474 

    Loss from operations 
     (15,365,751)  
     (16,378,474)

    Other income, net 
     343,724  
     955,003 

    Net loss 
    $(15,022,027) 
    $(15,423,471)

    Net loss available to common stockholders per share of common stock, basic and diluted 
    $(1.61) 
    $(1.83)

    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     9,355,710  
     8,401,047 

    Net loss 
    $(15,022,027) 
    $(15,423,471)
  
    Other comprehensive income: 

    Reclassification adjustment for interest earned on marketable securities included in net loss 
     -  
     (430,993)
  
    Change in unrealized gain on marketable securities 
     -  
     334,559 
  
    Comprehensive loss 
    $(15,022,027) 
    $(15,519,905)

See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

F-4

INDAPTUS
THERAPEUTICS, INC.

Consolidated
Statements of Stockholders’ Equity

    Shares  
    Amount  
    Capital  
    deficit  
    Income  
    Total 

    Common stock  
    Additional paid in  
    Accumulated  
    Accumulated Other Comprehensive  

    Shares  
    Amount  
    Capital  
    deficit  
    Income  
    Total 

    Balance, January 1, 2023 
     8,401,047  
    $84,011  
    $54,443,705